Literature DB >> 9557749

Identification of a full-length cDNA for an endogenous retrovirus of miniature swine.

D E Akiyoshi1, M Denaro, H Zhu, J L Greenstein, P Banerjee, J A Fishman.   

Abstract

Endogenous retroviruses of swine are a concern in the use of pig-derived tissues for xenotransplantation into humans. The nucleotide sequence of porcine endogenous retrovirus taken from lymphocytes of miniature swine (PERV-MSL) has been characterized. PERV-MSL is a type C retrovirus of 8,132 bp with the greatest nucleic acid sequence identity to gibbon ape leukemia virus and murine leukemia virus. Constitutive production of PERV-MSL RNA has been detected in normal leukocytes and in multiple organs of swine. The copy numbers of full-length PERV sequences per genome (approximately 8 to 15) vary among swine strains. The open reading frames for gag, pol, and env in PERV-MSL have over 99% amino acid sequence identity to those of Tsukuba-1 retrovirus and are highly homologous to those of endogenous retrovirus of cell line PK15 (PK15-ERV). Most of the differences in the predicted amino acid sequences of PK15-ERV and PERV-MSL are in the SU (cell attachment) region of env. The existence of these PERV clones will enable studies of infection by endogenous retroviruses in xenotransplantation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9557749      PMCID: PMC109691          DOI: 10.1128/JVI.72.5.4503-4507.1998

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  Transplantation in miniature swine. I. Fixation of the major histocompatibility complex.

Authors:  D H Sachs; G Leight; J Cone; S Schwarz; L Stuart; S Rosenberg
Journal:  Transplantation       Date:  1976-12       Impact factor: 4.939

Review 2.  Xenosis and xenotransplantation: addressing the infectious risks posed by an emerging technology.

Authors:  J A Fishman
Journal:  Kidney Int Suppl       Date:  1997-03       Impact factor: 10.545

3.  Characterization of a type C virus released from the porcine cell line PK(15).

Authors:  G J Todaro; R E Benveniste; M M Lieber; C J Sherr
Journal:  Virology       Date:  1974-03       Impact factor: 3.616

4.  Antigenic and biochemical characterization of the C-type particle of the stable porcine kidney cell line PK-15.

Authors:  W A Woods; T S Papas; H Hirumi; M A Chirigos
Journal:  J Virol       Date:  1973-11       Impact factor: 5.103

5.  Characterization of a novel murine leukemia virus-related subgroup within mammals.

Authors:  M Tristem; P Kabat; L Lieberman; S Linde; A Karpas; F Hill
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

6.  Xenotransplantation and xenogeneic infections.

Authors:  L E Chapman; T M Folks; D R Salomon; A P Patterson; T E Eggerman; P D Noguchi
Journal:  N Engl J Med       Date:  1995-11-30       Impact factor: 91.245

7.  Type C virus production by a continuous line of pig oviduct cells (PFT).

Authors:  A M Bouillant; A S Greig
Journal:  J Gen Virol       Date:  1975-05       Impact factor: 3.891

8.  Biologic and immunologic properties of porcine type C viruses.

Authors:  M M Lieber; C J Sherr; R E Benveniste; G J Todaro
Journal:  Virology       Date:  1975-08       Impact factor: 3.616

9.  Histological evidence of fetal pig neural cell survival after transplantation into a patient with Parkinson's disease.

Authors:  T Deacon; J Schumacher; J Dinsmore; C Thomas; P Palmer; S Kott; A Edge; D Penney; S Kassissieh; P Dempsey; O Isacson
Journal:  Nat Med       Date:  1997-03       Impact factor: 53.440

10.  Pathogenesis of of cytomegalovirus infection. I. Activation of virus from bone marrow-derived lymphocytes by in vitro allogenic reaction.

Authors:  L B Olding; F C Jensen; M B Oldstone
Journal:  J Exp Med       Date:  1975-03-01       Impact factor: 14.307

View more
  67 in total

1.  Lack of evidence of conserved lentiviral sequences in pigs with post weaning multisystemic wasting syndrome.

Authors:  A Bratanich; M Lairmore; W Heneine; C Konoby; J Harding; K West; G Vasquez; G Allan; J Ellis
Journal:  Can J Vet Res       Date:  1999-07       Impact factor: 1.310

2.  Infection in xenotransplantation.

Authors:  J A Fishman
Journal:  BMJ       Date:  2000-09-23

3.  Comparison of replication-competent molecular clones of porcine endogenous retrovirus class A and class B derived from pig and human cells.

Authors:  U Krach; N Fischer; F Czauderna; R R Tönjes
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

4.  Genome structure and thymic expression of an endogenous retrovirus in zebrafish.

Authors:  Ching-Hung Shen; Lisa A Steiner
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

5.  Retroviral restriction factors and infectious risk in xenotransplantation.

Authors:  Y Meije; R R Tönjes; J A Fishman
Journal:  Am J Transplant       Date:  2010-07       Impact factor: 8.086

6.  Extended analysis of the in vitro tropism of porcine endogenous retrovirus.

Authors:  C A Wilson; S Wong; M VanBrocklin; M J Federspiel
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

7.  Reliable classification and recombination analysis of porcine endogenous retroviruses.

Authors:  Nikolai Klymiuk; Bernhard Aigner
Journal:  Virus Genes       Date:  2005-05       Impact factor: 2.332

8.  The number of a U3 repeat box acting as an enhancer in long terminal repeats of polytropic replication-competent porcine endogenous retroviruses dynamically fluctuates during serial virus passages in human cells.

Authors:  G Scheef; N Fischer; U Krach; R R Tönjes
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

9.  Characterization of endogenous retroviruses in sheep.

Authors:  Nikolai Klymiuk; Mathias Müller; Gottfried Brem; Bernhard Aigner
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

10.  Identification and promoter analysis of PERV LTR subtypes in NIH-miniature pig.

Authors:  Yi-Deun Jung; Hong-Seok Ha; Sang-Je Park; Keon-Bong Oh; Gi-Sun Im; Tae-Hun Kim; Hwan-Hoo Seong; Heui-Soo Kim
Journal:  Mol Cells       Date:  2013-02-21       Impact factor: 5.034

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.